Warsaw

• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC) Ended
  2024-517678-12-00 9 2021-01-14 METASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LEAST ONE SYSTEMI
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia
• A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno- … Ended
  2023-503519-13-00 4 2020-12-14 Advanced Hepatocellular Carcinoma
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended
  2023-506932-33-00 4 2020-10-20 non-small cell lung cancer
• Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended
  2023-506933-32-00 4 2020-10-20 Non-small Cell Lung Cancer (NSCLC)
• Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended
  2023-506934-56-00 4 2020-10-20 Non-small Cell Lung Cancer
• A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit … Ended
  2024-517785-42-00 5 2020-10-08 Renal cell carcinoma (RCC)
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended
  2023-507303-55-00 4 2020-09-30 Alzheimer Disease
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended
  2023-506527-28-00 5 2020-06-29 Axial Spondyloarthritis
• A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv … Ended
  2022-502988-37-00 5 2020-06-19 Small cell lung cancer (SCLC)
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef … Ended
  2023-507897-42-00 4 2020-05-12 Prevention of oesophageal strictures in adult patients after endoscopi
• A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/ … Ended
  2023-503749-76-00 1 2020-03-06 Solid Tumors
• Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) Ended
  2023-509542-35-00 3 2020-03-02 Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD
• Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip … Ended
  2022-500418-24-00 10 2020-01-17 Locally Recurrent Inoperable or Metastatic Triple Negative Breast Canc
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• Ertugliflozin Pediatric Study Ended
  2022-501085-21-00 5 2019-11-29 Type 2 Diabetes Mellitus
• A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended
  2023-506528-95-00 5 2019-11-21 Psoriatic Arthritis

Showing 1,609–1,632 of 1,708 trials